GLEAMER’s Partnership with TeraRecon to Advance Clinical AI Capabilities on the Eureka Clinical AI Platform

The partnership integrates GLEAMER’s cutting-edge BoneView (FDA), BoneView (CE), and ChestView (CE) products into the Eureka Clinical AI platform, revolutionizing diagnostic capabilities. GLEAMER, a leading provider of AI solutions for medical imaging, is proud to announce its strategic partnership with Advanced visualization and AI leader TeraRecon,

The Léon Bérard Centre and GLEAMER sign a partnership to accelerate innovation in oncological imaging

GLEAMER, the European leader in artificial intelligence for radiology, and the Léon Bérard Centre, a Cancer Fight Centre (CLCC) in Lyon, France, have signed a strategic partnership to accelerate innovation in oncological imaging. Since 2017, the Léon Bérard Centre (CLB) is involved in projects using artificial

Gleamer raises €27 Million in series B to elevate the standard of care in radiology with AI

Gleamer is proud to announce a groundbreaking achievement: the successful completion of a Series B financing round, securing a remarkable €27 million in funding. This milestone marks a new chapter in Gleamer’s journey to revolutionize healthcare through cutting-edge technology. Supernova Invest leads the funding round, accompanied by co-leader Heal Capital

Gleamer and Imagerie Medicale du Parc Lyon (IMPL) announce a partnership to optimize patient care through AI

Gleamer and IMPL are pleased to announce their new partnership to optimize patient care in osteoarticular measurements through artificial intelligence. Gleamer has been supporting IMPL since 2021 with its BoneView algorithm, which assists in interpreting standard traumatic radiographs. This collaboration has led to a partnership to support

BoneView is the first AI solution to receive FDA clearance for pediatric use in fracture detection.

Paris, France – March 8, 2023 French MedTech start-up GLEAMER announced today that its AI-powered fracture detection solution, BoneView, has received FDA clearance for use in children over two years old. This marks a significant milestone for the company and the industry as a whole, as BoneView is now the